Income, growth, diversification: A compelling combination
Disclosure – Non-Independent Marketing Communication
This is a non-independent marketing communication commissioned by International Biotechnology Trust. The report has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibition on the dealing ahead of the dissemination of investment research.
This trust offers a blend of characteristics which might appeal to many investors…
Not many investors would turn down capital growth, a stable yield, and diversification from one of the most exciting sectors in the marketplace.
This is exactly whatInternational Biotechnology Trust (IBT)and its Fund Manager, SV Health Managers LLP have provided for the trust’s investors and why it is attracting a new and growing investor base.
IBT’s lead manager Carl Harald Janson aims to give investors in IBT exposure to the growth generated by companies in the biotechnology sector, as well as any outperformance the investment team can achieve with active management. Part of that growth is then paid to investors in the form of a dividend yield equivalent to 4% of its year-end NAV, the dividend being paid from capital reserves and split over two semi-annual tranches.
A yield of a different kind
Yield is increasingly hard to come by anywhere right now, and the search for it has driven many investors and fund managers into the same few companies in the market. UK equity income funds, for example, reportedly hold large overlapping positions in a handful of FTSE 100 dividend-payers, leading to a concentration of risk for income seeking investors.
IBT offers a differentiated income stream which is generated by converting some of the growth generated by its investments in global biotech companies into a dividend paid from the capital reserve.
In the current uncertain environment, many companies have been cutting or suspending their dividend payouts to preserve cash. Because IBT’s yield is paid out of its capital reserves rather than dividends from the companies it holds this means it is not reliant on dividends paid by the companies in which it invests; as long as they are growing at a sufficient rate, some of that growth can be harvested and paid out as income.
Investors should be aware that IBT’s dividend is based on its NAV which can fluctuate based on portfolio performance. Since its dividend policy was introduced in 2016, the trust has attracted more and more income-hungry investors and this, combined with strong performance, sector momentum and consistent fund management policy, has seen its discount to NAV turn to a premium.
There are several powerful drivers in the biotech space which should continue to support the trust’s healthy yield.
Among them are the supply and demand dynamics underpinning the sector.
On the supply side, the biotech industry is home to cutting-edge innovation in new drugs and treatments such as gene therapy or antibodies to tackle disease. The US Food and Drug Administration (FDA) is approving more new drugs than ever before, creating a supportive environment for drug development.
Then on the demand side are demographic and social trends, such as a growing elderly population globally and increased spending power in developing markets leading to an increasing need for healthcare.
As countries around the world become wealthier, spending on healthcare as a proportion of GDP rises, and this should continue to be a tailwind for biotechnology investors.
A vaccine for COVID
COVID-19 is already having a huge impact on the sector in many ways. There are over 10 clinical trials for vaccines and treatments happening across the whole industry as scientists scramble to create a vaccine in record time – perhaps even by the end of this year, where normally it takes five to ten years to produce one.
That said, COVID-19 has also caused issues for biotech, as it has for many other industries. Recruitment to clinical trials has slowed, some clinical trials have had to be halted, and international supply chains have faltered.
Visits to doctors and hospitals for non-essential treatments have fallen dramatically. However, IBT targets companies which develop drugs for unmet medical need which are less affected by this.
Strategies to temper risk
While COVID-19 research has led to sky-high valuations among some biotech companies, IBT’s investment team avoids chasing these names, as it is hard to predict at the moment which technologies will be successful and to what extent treatments or vaccines will be profitable.
Following a bull run for biotech between 2012 and 2015, valuations became stretched and investors feared the sector was entering bubble territory. Five years of consolidation followed, and valuations now don’t look excessive, the managers say, at around 12 times estimated earnings for the S&P Biotechnology Industry Index.
Volatility is something investors in biotech should expect, as it is a characteristic of the space, but IBT’s managers have strategies in place to mitigate it and smooth performance.
Chief among these is diversification, with a broad portfolio of over 90 companies straddling different sub-sectors, different size brackets and different stages of development.
This includes IBT’s investment in a venture capital fund holding unquoted biotech companies which, along with a few direct unquoted investments which accounts for 5-15% of the fund and is uncorrelated to the wider market.
The team also tries to reduce stock-specific risk by reducing or selling out of companies ahead of big binary events such as crucial drug trials. This helps them avoid big losses associated with failed trials but means they can buy back in when trials succeed and the asset is de-risked, and still catch some upside from the share price.
This approach has reduced volatility and supported long-term outperformance for International Biotechnology Trust.
To visit Kepler Trust Intelligence click here
To buy this trust click here
This report has been issued by Kepler Partners LLP. The analyst who has prepared this report is aware that Kepler Partners LLP has a relationship with the company covered in this report and/or a conflict of interest which may impair the objectivity of the research.
Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise and you may get back less than you invested when you decide to sell your investments. It is strongly recommended that if you are a private investor independent financial advice should be taken before making any investment or financial decision.
Kepler Partners is not authorised to market products or make recommendations to retail clients. This report has been issued by Kepler Partners LLP, is based on factual information only, is solely for information purposes only and any views contained in it must not be construed as investment or tax advice or a recommendation to buy, sell or take any action in relation to any investment.
The information provided on this website is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject Kepler Partners LLP to any registration requirement within such jurisdiction or country. In particular, this website is exclusively for non-US Persons. Persons who access this information are required to inform themselves and to comply with any such restrictions.
The information contained in this website is not intended to constitute, and should not be construed as, investment advice. No representation or warranty, express or implied, is given by any person as to the accuracy or completeness of the information and no responsibility or liability is accepted for the accuracy or sufficiency of any of the information, for any errors, omissions or misstatements, negligent or otherwise. Any views and opinions, whilst given in good faith, are subject to change without notice.
This is not an official confirmation of terms and is not a recommendation, offer or solicitation to buy or sell or take any action in relation to any investment mentioned herein. Any prices or quotations contained herein are indicative only.
Kepler Partners LLP (including its partners, employees and representatives) or a connected person may have positions in or options on the securities detailed in this report, and may buy, sell or offer to purchase or sell such securities from time to time, but will at all times be subject to restrictions imposed by the firm’s internal rules. A copy of the firm’s Conflict of Interest policy is available on request.